RapidAI, a San Mateo, CA-based company developing Artificial Intelligence (AI) and technology workflow solutions to combat life-threatening neurovascular, cardiac, and vascular diseases, announced $75 million in Series C funding.
The round was led by Vista Credit Partners, a subsidiary of Vista Equity Partners and a strategic financing partner focused on the enterprise software, data, and technology markets.
The funding aims to drive platform innovation to support more disease states and go-to-market functions to accelerate growth in new regions and product verticals.
“Hospitals are increasingly looking for RapidAI solutions to solve their critical needs, including helping care teams work more efficiently and support clinical decision making for better patient outcomes,” said Karim Karti, CEO of RapidAI.“RapidAI’s advanced clinical decision support (CDS) software goes beyond simple triage and notification to provide specific, relevant and contextual data with tremendous accuracy to satisfy these demands.Vista Credit Partners’ support and access to their expertise will advance our vision, technological innovation and go-to-market efforts as we further establish our leadership position in clinical AI solutions for life-threatening diseases.”
RapidAI has built a comprehensive portfolio of stroke solutions. This technology provides hospitals, regardless of size and imaging capabilities, with greater access to imaging and decision support, allowing them to address a wider population of stroke patients.
The company has expanded into new disease states with FDA-cleared modules for cerebral aneurysm management and the identification and notification of suspected central pulmonary embolisms. The company is also working on developing additional modules for other disease states.
Company: iSchemaView, Inc.
Raised: $75.0M
Round: Series C
Funding Month: July 2023
Lead Investors: Vista Credit Partners
Additional Investors:
Company Website: https://www.rapidai.com/
Software Category: Clinical AI Solution
About the Company: RapidAI has built a comprehensive portfolio of stroke solutions. The RapidAI stroke portfolio combines advanced imaging and workflow to enable physicians to make faster, more accurate triage or transfer decisions. It empowers clinicians to provide time-sensitive treatment and faster diagnosis. RapidAI is empowering physicians to make faster decisions for better patient outcomes.
Source: https://www.rapidai.com/press-release/rapid-announces-investment-led-by-vista-credit-partners